---
schema_version: "secwatch.filing_event.v1"
accession: "0001323885-26-000005"
form_type: "8-K"
ticker: "ATRC"
cik: "0001323885"
company_name: "AtriCure, Inc."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:22:09.266032+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AtriCure Q4 revenue $140.5M (+13.1% YoY); guides FY26 revenue $600-610M

## Summary
- Q4 2025 revenue $140.5M (+13.1% YoY); net income $1.8M ($0.04 EPS) vs net loss $0.33 per share in Q4 2024.
- FY 2025 revenue $534.5M (+14.9% YoY); net loss $11.4M ($0.24 loss per share) improved from $0.95 loss per share in 2024.
- FY 2025 adjusted EBITDA $61.8M (+98% vs $31.1M in 2024); Q4 adj. EBITDA $19.9M vs $12.7M.
- FY 2026 guidance: revenue ~$600-610M (12-14% growth); adj. EBITDA $80-82M; positive net income; adj. EPS $0.09-0.15.
- U.S. revenue $435.4M (+13.7%); international $99.2M (+20.2%); growth driven by cryoSPHERE MAX, AtriClip FLEX-Mini, EnCompass clamp.

## SEC filing metadata
- accession: 0001323885-26-000005
- form_type: 8-K
- ticker: ATRC
- cik: 0001323885
- company_name: AtriCure, Inc.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1323885/000132388526000005/0001323885-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1323885/000132388526000005/atrc-20260217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001323885-26-000005
- JSON: https://secwatch.observer/filing/0001323885-26-000005.json
- Plain text: https://secwatch.observer/filing/0001323885-26-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.